

**2** TECHNOLOGY PLATFORMS  **100** PRIORITIZED TARGETS IN **20** CANCER INDICATIONS

**8** PROPRIETARY PROGRAMS

**TCR-BASED CELL THERAPIES & BISPECIFICS**

**2** INDs   
APPROVED IN 2017

  EMPLOYEES  
**>150**

FUNDS RAISED  
**\$ >230m**

**3**  INDUSTRY PARTNERS

SEEKING **ONE** STRATEGIC  
**PARTNERSHIP** 

USING NOVEL  
**TARGETS** 

TO DEVELOP **BEST-IN-DISEASE**  
CELL THERAPIES & BISPECIFICS